Skip to main content

Table 2 Events, crude incidence rates and hazard ratios of events in the two treatment groups

From: Effects of background statin therapy on glycemic response and cardiovascular events following initiation of insulin therapy in type 2 diabetes: a large UK cohort study

  Statin use (N = 10,682) None (N = 2043)
Composite outcomea
 No of events/person-years 878/42,484 217/7032
 Absolute ratesb (95% CI) 20.7 (19.3–22.1) 30.9 (27.0–35.3)
 HRc (95% CI) 1 (reference) 1.53 (1.32–1.77)
 aHRd (95% CI) 1 (reference) 1.36 (1.15–1.62)
All-cause mortality
 No of events/person-years 415/43,503 177/7098
 Absolute rates (95% CI) 9.5 (8.7–10.5) 24.9 (21.5–28.9)
 HR (95% CI) 1 (reference) 2.61 (2.19–3.12)
 aHR (95% CI) 1 (reference) 1.89 (1.51–2.37)
Acute myocardial infarction (AMI)
 No of events/person-years 60/43,377 5/7094
 Absolute rates (95% CI) 1.4 (1.1–1.8) 0.7 (0.3–1.7)
 HR (95% CI) 1 (reference) 0.50 (0.20–1.25)
 aHR (95% CI) 1 (reference) 0.88 (0.35–2.23)
Non-fatal stroke
 No of events/person-years 401/42,643 34/7051
 Absolute rates (95% CI) 9.4 (8.5–10.4) 4.8 (3.4–6.7)
 HR (95% CI) 1 (reference) 0.51 (0.36–0.72)
 aHR (95% CI) 1 (reference) 0.55 (0.38–0.81)
  1. aComposite outcome is a three-point MACE including all-cause mortality, non-fatal acute myocardial infarction (AMI) and non-fatal stroke
  2. bAbsolute rate at 1000 person-years
  3. cHR (unadjusted hazard ratio)
  4. daHR (adjusted hazard ratio). Adjusted for age, gender, duration of insulin use, albumin, glomerular filtration rate, lipid profile, and coronary heart disease